









Markets
/
Stocks
/
nasdaq-juns
/

Jupiter Neurosciences Inc

JUNS

1.530USD

+0.050+3.38%

Close 10/24, 16:00（ET）Quotes delayed by 15 min

53.29MMarket Cap

LossP/E TTM



Jupiter Neurosciences Inc

1.530

+0.050+3.38%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Jupiter Neurosciences Inc

Currency: USD Updated: 2025-10-24

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Jupiter Neurosciences Inc's Score

Industry at a Glance

Industry Ranking

141 / 501

Overall Ranking

267 / 4683

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Jupiter Neurosciences Inc Highlights

StrengthsRisks

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Fairly Valued

The company’s latest PE is -8.13, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 80.88K shares, decreasing 79.49% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-24

The company's current financial score is 6.96, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.96

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Jupiter Neurosciences Inc's Company Valuation

Currency: USD Updated: 2025-10-24

The company’s current valuation score is 6.45, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -8.13, which is -41.44% below the recent high of -4.76 and -4025.46% above the recent low of -335.30.

Score

Industry at a Glance

Previous score

6.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 141/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-24

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

0.000

Target Price

0.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

551

Total

Median

Average

Company name

Ratings

Analysts

Jupiter Neurosciences Inc

JUNS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-24

The company’s current price momentum score is 6.87, which is higher than the Biotechnology & Medical Research industry's average of 6.68. Sideways: Currently, the stock price is trading between the resistance level at 1.77 and the support level at 1.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.89

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Neutral

RSI(14)

49.603

Neutral

STOCH(KDJ)(9,3,3)

30.059

Neutral

ATR(14)

0.128

High Vlolatility

CCI(14)

-84.970

Neutral

Williams %R

66.667

Sell

TRIX(12,20)

0.136

Sell

StochRSI(14)

37.816

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.540

Sell

MA10

1.540

Sell

MA20

1.592

Sell

MA50

1.487

Buy

MA100

1.447

Buy

MA200

1.330

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-24

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rosen (Christer)

11.55M

+0.03%

Wahlestedt (Claes M.D., Ph.D.)

2.80M

Hayward (Marshall A Ph.D.)

2.38M

Brothers (Shaun P.)

1.70M

Rosen (Alexander Gustaf Erik)

452.86K

Silva (Alison D)

112.78K

+0.67%

Elmasri (Saleem C)

66.29K

UBS Financial Services, Inc.

53.92K

-60.25%

Brady (Allison W)

21.75K

Geode Capital Management, L.L.C.

15.86K

Risk Assessment

Currency: USD Updated: 2025-10-24

The company’s current risk assessment score is 1.90, which is lower than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.